Should I buy or sell RenovoRx stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RenovoRx in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RNXT shares. View RNXT analyst ratings or view top-rated stocks .

What is RenovoRx's stock price target for 2024?

3 Wall Street research analysts have issued 12 month target prices for RenovoRx's stock. Their RNXT share price targets range from $4.00 to $13.00. On average, they expect the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 596.7% from the stock's current price. View analysts price targets for RNXT or view top-rated stocks among Wall Street analysts .

How have RNXT shares performed in 2024?

RenovoRx's stock was trading at $2.29 at the beginning of 2024. Since then, RNXT stock has decreased by 46.7% and is now trading at $1.22. View the best growth stocks for 2024 here .

When is RenovoRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our RNXT earnings forecast .

When did RenovoRx IPO?

RenovoRx (RNXT) raised $18 million in an initial public offering on Thursday, August 26th 2021. The company issued 1,800,000 shares at $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO.

How do I buy shares of RenovoRx?

Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RNXT

RenovoRx (RNXT) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free RNXT Stock Alerts

$1.22

+0.03 (+2.52%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.15
▼
$1.29
50-Day Range: $1.14
▼
$1.78
52-Week Range: $0.53
▼
$3.29

Volume: 5,264 shs
Average Volume: 63,403 shs
Market Capitalization: $20.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

Get RenovoRx alerts:

RenovoRx MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 596.7% Upside
$8.50 Price Target
Short Interest: Healthy
0.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.08
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.94 out of 5 stars

Medical Sector

805th out of 918 stocks

Pharmaceutical Preparations Industry

354th out of 402 stocks

3.3

Analyst's Opinion

Consensus Rating
RenovoRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
RenovoRx has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.13% of the float of RenovoRx has been sold short.
Short Interest Ratio / Days to Cover
RenovoRx has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in RenovoRx has recently increased by 12.18%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
RenovoRx does not currently pay a dividend.
Dividend Growth
RenovoRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RNXT.

1.7

News and Social Media Coverage

News Sentiment
RenovoRx has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for RenovoRx this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for RNXT on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, RenovoRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.00% of the stock of RenovoRx is held by insiders.
Percentage Held by Institutions
Only 3.10% of the stock of RenovoRx is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of RenovoRx is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of RenovoRx is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About RenovoRx Stock (NASDAQ:RNXT)

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.

RNXT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RNXT Stock News Headlines

April 18, 2024 | fr.investing.com

RenovoRx répond aux exigences du Nasdaq en matière de capitaux propres

April 18, 2024 | businesswire.com

RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 16, 2024 | businesswire.com

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

April 15, 2024 | finance.yahoo.com

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

April 15, 2024 | businesswire.com

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

April 8, 2024 | investorplace.com

RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023

April 8, 2024 | investorplace.com

RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 8, 2024 | businesswire.com

RenovoRx Announces $11.1 Million at Market Private Placement

April 5, 2024 | businesswire.com

RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024

March 12, 2024 | finance.yahoo.com

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024

March 10, 2024 | investing.com

RenovoRx announces key leadership promotions

March 8, 2024 | fr.investing.com

RenovoRx annonce des promotions à des postes clés

March 8, 2024 | finance.yahoo.com

RenovoRx Highlights Key Leadership Promotions

February 6, 2024 | fr.investing.com

RenovoRx obtient un financement pour un essai de phase III sur le cancer

January 29, 2024 | msn.com

RenovoRx closes $6.1M private placement

January 29, 2024 | finance.yahoo.com

RenovoRx Closes $6.1 Million Private Placement

December 21, 2023 | finance.yahoo.com

RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer

December 19, 2023 | finance.yahoo.com

RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

December 13, 2023 | finance.yahoo.com

RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform

December 9, 2023 | morningstar.com

RenovoRx Inc RNXT

November 16, 2023 | msn.com

Maxim Group Downgrades RenovoRx (RNXT)

November 16, 2023 | finance.yahoo.com

RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

November 14, 2023 | msn.com

RenovoRx GAAP EPS of -$0.13

November 14, 2023 | finance.yahoo.com

RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights

October 9, 2023 | finance.yahoo.com

RenovoRx, Inc. (RNXT) Stock Historical Prices & Data - Yahoo Finance

See More Headlines

Receive RNXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RNXT
CUSIP: N/A
CIK: 1574094
Web: www.renovorx.com
Phone: 650-284-4433
Fax: 650-397-4433
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.50
High Stock Price Target: $13.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +596.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,230,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -2,860.14%
Return on Assets: -261.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.16
Quick Ratio: 1.16

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.28) per share
Price / Book: -4.36

Miscellaneous

Outstanding Shares: 16,870,000
Free Float: 15,348,000
Market Cap: $20.58 million
Optionable: Not Optionable
Beta: 1.04

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Ramtin Agah M.D. (Age 58)
Founder, Chairman of Board & Chief Medical Officer
Comp: $380.04k
Mr. Shaun R. Bagai (Age 47)
CEO & Director
Comp: $717.75k
Ms. Leesa Gentry (Age 54)
Chief Clinical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RNXT Stock Analysis - Frequently Asked Questions

Should I buy or sell RenovoRx stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RenovoRx in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RNXT shares.
View RNXT analyst ratings or view top-rated stocks.
What is RenovoRx's stock price target for 2024?: 3 Wall Street research analysts have issued 12 month target prices for RenovoRx's stock. Their RNXT share price targets range from $4.00 to $13.00. On average, they expect the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 596.7% from the stock's current price.
View analysts price targets for RNXT or view top-rated stocks among Wall Street analysts.
How have RNXT shares performed in 2024?: RenovoRx's stock was trading at $2.29 at the beginning of 2024. Since then, RNXT stock has decreased by 46.7% and is now trading at $1.22.
View the best growth stocks for 2024 here.
When is RenovoRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our RNXT earnings forecast.

When did RenovoRx IPO?: RenovoRx (RNXT) raised $18 million in an initial public offering on Thursday, August 26th 2021. The company issued 1,800,000 shares at $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO.
How do I buy shares of RenovoRx?: Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RNXT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

RenovoRx (RNXT) Stock Price, News & Analysis

RenovoRx MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About RenovoRx Stock (NASDAQ:RNXT)

RNXT Stock Price History

RNXT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RNXT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™